Edwards Lifesciences Corporation (NYSE:EW) – Stock analysts at SunTrust Banks boosted their Q3 2017 earnings per share estimates for shares of Edwards Lifesciences Corporation in a report issued on Monday. SunTrust Banks analyst B. Nudell now anticipates that the medical research company will post earnings of $0.85 per share for the quarter, up from their previous estimate of $0.83. SunTrust Banks currently has a “Buy” rating and a $14.00 target price on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q4 2017 earnings at $0.92 EPS, FY2017 earnings at $3.78 EPS, Q1 2018 earnings at $1.10 EPS, FY2018 earnings at $4.18 EPS, FY2019 earnings at $4.76 EPS and FY2020 earnings at $5.37 EPS.
Several other analysts have also recently weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a research note on Sunday. Royal Bank Of Canada reaffirmed a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday. Cowen and Company reaffirmed an “outperform” rating and set a $135.00 price objective (up from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Barclays PLC upped their price objective on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 27th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $121.13.
ILLEGAL ACTIVITY WARNING: “SunTrust Banks Analysts Lift Earnings Estimates for Edwards Lifesciences Corporation (NYSE:EW)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/19/suntrust-banks-analysts-lift-earnings-estimates-for-edwards-lifesciences-corporation-nyseew-updated-updated.html.
Shares of Edwards Lifesciences Corporation (EW) opened at 115.18 on Tuesday. The stock’s 50 day moving average price is $117.20 and its 200-day moving average price is $104.28. The company has a market cap of $24.25 billion, a PE ratio of 34.93 and a beta of 0.63. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.
Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The company had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 earnings per share.
Large investors have recently bought and sold shares of the company. Quadrant Capital Group LLC raised its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the period. YorkBridge Wealth Partners LLC purchased a new stake in Edwards Lifesciences Corporation during the first quarter valued at $110,000. NEXT Financial Group Inc raised its stake in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the period. Cornerstone Advisors Inc. raised its stake in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares during the period. Finally, Alexandria Capital LLC raised its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the period. Institutional investors own 83.80% of the company’s stock.
In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 49,100 shares of the stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $109.71, for a total value of $5,386,761.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 19,100 shares of the stock in a transaction on Monday, May 8th. The stock was sold at an average price of $110.34, for a total transaction of $2,107,494.00. The disclosure for this sale can be found here. Insiders sold 184,951 shares of company stock worth $20,780,242 over the last 90 days. 2.13% of the stock is currently owned by company insiders.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.